Brian M. Connelly

Chief Executive Officer

TheracosBio, LLC

• Lead a MA-based biotech company through the launch of an FDA-approved SGLT2 inhibitor for the treatment of Type 2 diabetes and the development of a pipeline of other products.

Co-Founder and Chief Operating Officer

IncreVet, Inc.

• Co-Founder and COO of IncreVet, Inc., an innovative animal health drug development company that developed the first FDA-approved oral treatment for feline diabetes before being acquired.

Senior Manager for Business Development

IDEXX Laboratories, Inc.

• IDEXX Laboratories, Inc. where he was both an Associate General Counsel in the company’s legal department and a Senior Manager for Business Development helping IDEXX grow its reference laboratory network through acquisitions both inside and outside the United States

Prior to joining IDEXX, Brian practiced law at a large Boston law firm, representing technology, life sciences, and software companies. Additionally, he served as legal counsel to the Committee on Education and the Workforce in the U.S. House of Representatives, served as legal counsel to the U.S. Senate's Committee on Governmental Affairs and clerked for the Honorable Clyde Hamilton of the United States Court of Appeals for the Fourth Circuit.

• Sale of Bio-Pharm, Inc. to Torrent Pharmaceuticals
• Merger of Motif Micro, Inc. to YPB Group Limited
• Sale of AesRx (with a Phase II sickle cell program) to Baxter International
• Alnylam Pharmaceuticals acquisition of Sirna Therapeutics from Merck for $175 million plus milestones and royalties
• Spin-out of Florida Biologix business from University of Florida, and equity financing
• Strategic investment from IMS Health in CliniWorks
• Spin-out and equity financing of Mellitus from Harvard Medical School
• Acquisition of PharmPro division of FluidAir by Mutual Pharmaceutical Company
• Business combination of BioSTAR West and Hawaii Chitopure to form Synedgen
• Long-Term Manufacturing and Supply Agreement between Bio- Pharm, Inc. and G&W Laboratories, Inc.
• Acquisition of all of the shares of Porogen Corporation by Air Liquide Advanced Technologies U.S. LLC (pending)
• Acquisition of all of the shares of Vgo Communications, Inc. by Vecna Technologies, Inc.
• Sale of a controlling interest in HighRes Biosolutions, Inc. to NewtrAx

Leasing Work

• Lease of approximately 66,000 RSF in Watertown, MA between Kala Pharmaceuticals, Inc. and 480 Arsenal Group, LLC
• Lease of approximately 38,000 RSF in Cambridge, MA between Unum Therapeutics, Inc. and King Street Properties
• Lease of approximately 15,000 RSF HQ office and Warehouse space in Nassau, NY between Level Solar, Inc. and Steel 327 New South Road LLC
• Lease of approximately 48,500 RSF of space in Cambridge, MA between Alnylam, Inc. and RREEF America REIT II CORP
• Lease of approximately 4,800 RSF of office space in Seattle, WA between Atara Biotherapeutics, Inc. and BPG Rock Westlake, LLC
• Lease of approximately 3,500 RSF of office space in King of Prussia, PA between Paratek Pharma LLC and Atlantic American Properties Trust
• Lease of approximately 37,500 RSF of office and lab space in Cambridge, MA between Dicerna Pharmaceuticals, Inc. and King Street Properties
• Lease of approximately 46,000 RSF of office and lab space in Waltham, MA between NetBio, Inc. and 266 & 275 Second Avenue, LLC
• Lease of approximately 5,200 RSF of office space in Billerica, MA between Raindance Technologies, Inc. and Fortune Partners, LC